Intensive glucose control and macrovascular outcomes in type 2 diabetes.
about
Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - SummaryTargeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitusInsulin and glucose-lowering agents for treating people with diabetes and chronic kidney diseaseIntensive glucose control versus conventional glucose control for type 1 diabetes mellitusGlucose lowering therapies for chronic kidney disease and kidney transplantationTargeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitusDapagliflozin for type 2 diabetes mellitusIntensive glucose control versus conventional glucose control for type 1 diabetes mellitusTargeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitusEffect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trialsStandards of medical care in diabetes--2012Diabetes Drugs and Cardiovascular SafetyPolypharmacy in the Aging Patient: A Review of Glycemic Control in Older Adults With Type 2 DiabetesGlycemic Targets in Diabetes Care: Emerging Clarity after AccordAvoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetesGlycosylated hemoglobin in relationship to cardiovascular outcomes and death in patients with type 2 diabetes: a systematic review and meta-analysisInsulin resistance as a physiological defense against metabolic stress: implications for the management of subsets of type 2 diabetesCardiovascular importance of hyperglycemia and hypoglycemiaPrognostic significance of hemoglobin A1c level in patients hospitalized with coronary artery disease. A systematic review and meta-analysisGlycemic control and cardiovascular disease: what's a doctor to do?Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial.Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association.Current perspectives on cardiovascular outcome trials in diabetesHeart Failure: a Major Cardiovascular Complication of Diabetes MellitusEfficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozinDifferential effects of drug interventions and dietary lifestyle in developing type 2 diabetes and complications: a systems biology analysis in LDLr-/- miceStandards of medical care in diabetes--2013Genetic Predictors of Cardiovascular Mortality During Intensive Glycemic Control in Type 2 Diabetes: Findings From the ACCORD Clinical Trial.What's wrong with too low? Is hypoglycemia a marker or a cause of CVD and mortality risk?Diabetic cardiomyopathy: pathophysiology and clinical featuresRecommending aspirin for primary prevention in diabetic patients: what may we conclude from the data?Effects of intensive glycaemic control on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial.Standards of medical care in diabetes--2010.Impact of symptomatic hypoglycemia on medication adherence, patient satisfaction with treatment, and glycemic control in patients with type 2 diabetes.Gaps and barriers in the control of blood glucose in people with type 2 diabetes.Diabetes and cardiovascular disease: from evidence to clinical practice - position statement 2014 of Brazilian Diabetes Society.Effect of sitagliptin on the echocardiographic parameters of left ventricular diastolic function in patients with type 2 diabetes: a subgroup analysis of the PROLOGUE study.Effect of diet on type 2 diabetes mellitus: A review.Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Continued Up-Titration of Insulin Glargine U100 in Patients with Type 2 Diabetes in the USA.
P2860
Q22241288-9F8556DD-0917-45E3-AD73-AB6D9AC5CBB2Q22241786-CAAF7038-872A-4096-B57E-9C97FDB920B6Q24186667-E488A59A-E9C7-4581-B0EF-3CAC531CB99BQ24188192-BD3BD611-9A78-4AEE-9C0B-21A5CC52E2D2Q24200376-76B3E637-7421-461C-B5FB-CA2588EACDD6Q24201814-CED2464A-BF86-4F0E-9198-B21ED140BD65Q24202505-A4B29C86-AEEE-428B-A48A-CB36D109395CQ24234557-A84A9BF1-4499-4D7B-A286-6B603A05B945Q24234960-FF201B26-B3A3-454D-8533-A6DDEA8D0018Q24236456-A4FE498F-1114-4D8C-9035-482548F0B36AQ24628988-889310A8-164E-4321-A7E2-C81BF7650F5BQ24632533-E49FB1BE-242F-4490-9C9E-86062318F344Q26746085-96F89D84-E961-49EF-8ADE-E0094890AABFQ26767283-B6C9B9CA-B3FB-4EFE-BA21-E5FADDD01FA1Q26795380-3CBCC479-9C6F-42D2-B3D8-975648113916Q26827955-66F29320-60FD-4F2F-8F16-F457700A7B71Q26860467-72FDAF4B-D0AF-43A2-8D78-372F4EBF2AACQ26866924-60140A7D-5664-466B-B570-76A31758CDDAQ26999390-5FAA575D-C6A9-4A80-B832-AFC94302CF33Q27021243-01476B94-9812-4454-94E4-B82DB6608469Q27024469-14438D83-3ECF-4414-9CCF-1309845D51F2Q27301948-C2E32B3A-888C-418A-BD90-E6DC04C60689Q27687851-BC25B420-B8FC-4646-B8A8-6ABB2AB9696DQ28066006-B585CEA9-6F83-4709-91F9-CAFA855C0008Q28066310-25417623-7686-40D7-9AD9-EA409F41C156Q28250844-B6250B81-A80A-4EDD-8ACA-7C0F2F102F46Q28486194-44EEC81E-D246-4F71-AF0A-6E27EBBE0613Q29620309-D1B27B3D-BDFD-47C3-BB1D-7FC8FD62F35AQ30276113-B21E717A-9521-47C1-9C2B-CE831AC32FFBQ30452665-9B030033-80ED-49EA-95C1-35B895A8C2B6Q30457504-C33BF455-9F28-4891-B004-5FEFB24B4338Q30582282-A94B659D-E96A-4538-A97A-C71DE4535EB1Q30840447-9439A200-D8FE-4789-B9E4-E98CFFF2CA4FQ33554238-2C7435B9-3C27-43AB-8F5F-86CF8FDE78C2Q33573537-C02053E9-A769-4CFC-A3F8-52E52F0519F3Q33641379-4758BF03-6D53-4C85-B5B2-F82FB96A85E3Q33647298-0EE77F31-BAAA-41D4-AD72-29736273C24EQ33660548-B3E2B002-6A9D-4F0C-A9E7-C858E6FE18EAQ33662454-8E834F98-F88A-4A86-9C7E-A831D7D9E546Q33700904-DA051794-1E3D-4E78-B3E6-AE397938D907
P2860
Intensive glucose control and macrovascular outcomes in type 2 diabetes.
description
2009 nî lūn-bûn
@nan
2009 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Intensive glucose control and macrovascular outcomes in type 2 diabetes.
@ast
Intensive glucose control and macrovascular outcomes in type 2 diabetes.
@en
Intensive glucose control and macrovascular outcomes in type 2 diabetes.
@nl
type
label
Intensive glucose control and macrovascular outcomes in type 2 diabetes.
@ast
Intensive glucose control and macrovascular outcomes in type 2 diabetes.
@en
Intensive glucose control and macrovascular outcomes in type 2 diabetes.
@nl
prefLabel
Intensive glucose control and macrovascular outcomes in type 2 diabetes.
@ast
Intensive glucose control and macrovascular outcomes in type 2 diabetes.
@en
Intensive glucose control and macrovascular outcomes in type 2 diabetes.
@nl
P2093
P50
P1433
P1476
Intensive glucose control and macrovascular outcomes in type 2 diabetes
@en
P2093
Control Group
F M Turnbull
M Woodward
R J Anderson
R P Byington
P2860
P2888
P304
P356
10.1007/S00125-009-1470-0
P577
2009-08-05T00:00:00Z
P5875
P6179
1043090546